If 400m+ people live with COPD, why aren’t we talking about it? In the latest Behind the Science podcast, Dr. Kat Arney, Prof. Dave Singh and Dr. Kaivan Khavandi explore how COPD affects everyday life and why severe exacerbations, or attacks, can have such serious consequences on those living with the condition. Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.​ Exploring how today's discoveries are shaping tomorrow's health 'I had dreams': How HIV care has evolved across a generation 'Long-acting options are the future to prevent transmission of HIV' ‘It’s always there’: Learning to live with chronic hepatitis B ‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development Antibody-drug conjugates: Advancing the search for more targeted cancer treatment Mapping disease at the cellular level: A single-cell revolution in drug discovery Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus 'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk' 'We’re innovating to help keep COPD patients out of hospital and exacerbation-free' 'Prevention is the best medicine to stop disease before it starts' We announced our second quarter 2026 results on Tuesday 28 July